NextCure joins Merck in an ovarian target
But the former is paying a fraction of what Merck shelled out for raludotatug.
ASCO 2025 – Lilly makes a folate foray against Genmab
LY4170156 looks similar to Genmab’s rina-S, but cost Lilly a lot less.
ASCO 2025 – Amgen gets one over on Zai Lab
Imdelltra seems headed for full approval, raising questions about Zai’s accelerated plan.
ASCO 2025 – Enhertu mounts its first-line charge
Enhertu plus Perjeta shows a convincing progression-free survival benefit over a Perjeta triplet.
ASCO 2025 – Trodelvy heads for the front line
Gilead’s TROP2 ADC sets the bar for Astra/Daiichi’s Datroway in first-line TNBC.
The month ahead: June’s upcoming events
Crunch time approaches for UroGen.
